Article: NitroMed, Inc. Reports Financial Results for Fourth Quarter and Full Year 2004 -Conference Call March 10 at 5:00 PM ET-.

Article: NitroMed Restructures R&D Operations; Extended Release ...
Business Wire;  March 30, 2006 ;     700+ words ... ... marketing and sales of BiDil; unanticipated difficulties ... approvals to market and sell BiDil; adverse side effects experienced by patients taking BiDil; the Company's ability ... Form 10-K for the year ended December 31, 2005, which has been ...

Article: NitroMed Announces Agreement to Sell BiDil(R) Drug ...
Business Wire;  October 23, 2008 ;     700+ words ... ... to the transferred assets. BiDil (isosorbide dinitrate/hydralazine ... results of operations of the BiDil drug business as a whole or ... have signed a deal to sell the BiDil drug business with a well ... on Form 10-K for the year ended December 31, 2007 and its proxy statement ...

Article: FDA Schedules Advisory Committee Review of BiDil.
Business Wire;  April 29, 2005 ;     700+ words ... ... investigational drug BiDil(R). BiDil is the Company's product ... and inflammatory diseases. BiDil, the Company's lead product ... approvals to market and sell BiDil and other factors discussed ... on Form 10-K for the Year ended December 31, 2004, which is filed ...

Article: BiDil(R) Data to be Presented at American Heart ...
Business Wire;  November 11, 2005 ;     700+ words ... ... that feature post-approval analyses of BiDil(R) (isosorbide dinitrate/hydralazine ... held from November 13 - 16 in Dallas. BiDil was approved in June of this year by the ... self-identified black patients. The BiDil data to be presented further substantiate ...

Article: BiDil to Remain on the Market NitroMed Cuts Sales Force, ...
BIOWORLD Today;  January 17, 2008 ;     700+ words ... ... promotional activities for its heart failure drug BiDil (isosorbide dinitrate and hydralazine hydrochloride ... marketing activities will cease for the drug, BiDil will remain on the market. "We plan to keep BiDil available through all ordinary channels like ...

Article: BiDil(R) Gains Broad Preferred Status on Pharmacy Benefit ...
Business Wire;  September 24, 2007 ;     700+ words ... ... the reimbursement and formulary status of BiDil continues to improve. To date, approximately ... United States, have affordable access to BiDil. The company defines 'affordable' as ... payments for patients are approximately $25. BiDil([R]), the fixed-dose combination ...

Article: BIDIL HAS SHOWN REDUCTIONS IN DEATH OF BLACK HEART ...
Biotech Business;  May 1, 2007 ;     700+ words ... ... used in V-HeFT I and V-HeFT II, and BiDil, the proprietary fixed dose combination ... other and neither were bioequivalent to BiDil, according to FDA requirements. The study ... results in decreasing mortality, only BiDil has shown significant reductions in death ...